. Characterisation of HPV status, radiosensitivity and metabolic pathway expression of 14 HNSCC cell lines. S1A. Expression of high-risk HPV genes E2, E6, and E7 was tested and pooled. 14 HNSCC cell lines were tested for HPV16, HPV18, HPV33, and HPV52. Shown are fragments per million mapped fragments (FPM) for all high-risk HPV types for all cell lines. S1B. Radiosensitivity data of 14 HNSCC cell lines was fitted using the linear quadratic model. The dose permitting 37% survival (D37) was interpolated from this model using the generated α and β values. Shown are the α and β for each cell line, and the corresponding D37. S1C. D37 data were interpolated from survival curves in 1B using linear quadratic model fitting. D37 data are shown for 10 HPV-ve and 4 HPV+ve cell lines respectively. Statistical test: two-sided t-test with Welch's correction. S1D. Overview of metabolic pathway expression in four radioresistant vs. four radiosensitive HNSCC cell lines. Shown are genes that were enriched (red) or depleted (green) in radioresistant vs radiosensitive cells by at least a 1.5 fold change in either direction. Figure S2 . ACLY expression does not differ between HPV+ve and HPV-ve cell lines. Gene expression of ACLY was measured in 14 HNSCC cell lines using smMIPs. Comparison of ACLY expression between HPV+ve and HPV-ve cell lines was done using an unpaired, two-sided t-test with Welch's correction. FPM: fragments per million. Figure S3 . ACLY, but not FAS, inhibition leads residual DNA damage and radiosensitisation. S3A. Depletion of ACLY expression in UT-SCC-15 cells was performed using 0.5 or 2.5µg pooled siRNA for 72 hours, followed by confirmation by RT-qPCR. Error bars indicate standard deviation of three technical replicates. S3B. ACLY was depleted in UT-SCC-15 cells using pooled ACLY siRNA for 72 hours. Subsequently, cells were plated for a colony forming assay and irradiated with the indicated 2, 4, 6, or 8 Gy. Error bars indicate standard deviation of three technical replicates. S3C-D. UM-SCC-6 (A) and UT-SCC-5 (B) cells were treated with 5 µM BMS303141 or DMSO control for 6 hours and irradiated with 2 Gy. 24 hours post-irradiation, quantification of 53BP1 foci was performed. Shown are percentages of cells containing a number of 53BP1 foci per nucleus. Bins indicate the following: 0: 0-4 foci; 5: 5-9 foci etc. SE-F. UM-SCC-6 (C) or UT-SCC-5 cells were treated with 10 µM 10 C75 or DMSO control for 6 hours and were irradiated with 2 Gy. Quantification of cells positive for 53BP1 foci in UM-SCC-6 (C) and UT-SCC-5 (D) cells. Shown are mean percentages of three biological replicates and indicates cells that are positive for 53BP1 (>5 53BP1 foci per nucleus) in a single plane of view. SG. UT-SCC-5 cells were treated with 10 µM C75 or DMSO control for 6 hours and irradiated with 2, 4, or 6 Gy. Survival was determined by colony formation assay. Shown are mean values of two biological repeats with three technical replicates each. Figure S4 . ACLY is not associated with recurrence free survival outcome. S4A-B. Kaplan-Meier analysis of a TCGA cohort of HNSCC patients that have high or low ACLY expression based on the optimal cut-off point for overall survival. Shown are plots for recurrence free survival of HNSCC patients that received radiotherapy (A) and patients that did not (B).
